A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801)-Reference-Cited by-同舟云学术

A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non–Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801)

Published:2021-03 Issue:2 Volume:22 Page:147-151
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Asahina Hajime,Tanaka Kentaro^ORCID,Morita Satoshi,Maemondo Makoto,Seike Masahiro,Okamoto Isamu,Oizumi Satoshi,Kagamu Hiroshi,Takahashi Kazuhisa,Kikuchi Toshiaki,Isobe Takeshi,Sugio Kenji,Kobayashi Kunihiko

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference16 articles.

1. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis;Zhang;Oncotarget,2016

2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoparticle-based targeted therapy through EGFR tyrosine kinase inhibitors and their recent advances in lung cancer therapy;Exploration of Medicine;2024-07-14

2. Effect of anti-CD3-EGFR bispecific antibody-labeled DCCIK immune cells on proliferation of lung cancer cells;Tropical Journal of Pharmaceutical Research;2024-06-25

3. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04

4. Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer;Aging;2024-01-11

5. Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer;International Journal of Molecular Sciences;2024-01-09